Kasasbeh Mahar Zaid, Al-Rababˈah Eilaf Mohammad, Khasawneh Rawand A, Asfar Fadi N, Al-Shatnawi Samah F, Al-Sawalha Nour A
Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.
Center of Pharmacometrics and System Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Florida, United States of America.
PLoS One. 2025 Sep 11;20(9):e0330522. doi: 10.1371/journal.pone.0330522. eCollection 2025.
Peripheral artery disease (PAD) is a common atherosclerotic vascular condition associated with many complications. The specific effect of angiotensin receptor blockers (ARBs) on the short-term complications in PAD patients has not been explored before.
This study aimed to evaluate the association between ARBs use and the disease severity, progression, the frequency of surgical interventions, and arterial occlusion rates among users.
A retrospective cohort study was conducted at King Abdullah Ⅱ Hospital, including 133 patients followed between 2019 and 2024. The cohort was divided into two groups based on their exposure to ARBs: the ARBs group and the control group. Data related to patient demographics, clinical characteristics, medical history, laboratory results, vital signs, in addition to clinical outcomes were extracted from electronic medical records. Statistical analysis was performed using SPSS version 27.0.
Among the participants, 24.8% experienced amputation, with 21.1% in the control group compared to 3.8% in the ARBs group. ARBs group has 79.2% lower Limb amputation (P-value 0.011; OR= 0.208, 95% CI 0.062-0.700) and 71% lower likelihood of having advanced PAD stage (stages III and IV) (P-value = 0.034, OR= 0.294, 95% CI = 0.095-0.911) compared to the control group. Linear regression analysis showed that the ARBs group has a decreased frequency of revascularization procedures (P-value 0.025;95% CI -1.004 - - 0.068).
ARBs may serve as a promising protective treatment option for PAD patients, potentially benefiting disease progression by lowering the risk of amputation and reducing the need for revascularization procedures.
外周动脉疾病（PAD）是一种常见的动脉粥样硬化性血管疾病，伴有许多并发症。血管紧张素受体阻滞剂（ARB）对PAD患者短期并发症的具体影响此前尚未得到探讨。
本研究旨在评估使用ARB与疾病严重程度、进展、手术干预频率以及使用者动脉闭塞率之间的关联。
在阿卜杜拉国王二世医院进行了一项回顾性队列研究，纳入了2019年至2024年期间随访的133例患者。根据是否使用ARB将队列分为两组：ARB组和对照组。从电子病历中提取与患者人口统计学、临床特征、病史、实验室检查结果、生命体征以及临床结局相关的数据。使用SPSS 27.0版进行统计分析。
在参与者中，24.8%经历了截肢，对照组为21.1%，而ARB组为3.8%。与对照组相比，ARB组肢体截肢率降低79.2%（P值0.011；OR = 0.208，95%CI 0.062 - 0.700），晚期PAD阶段（III期和IV期）的可能性降低71%（P值 = 0.034，OR = 0.294，95%CI = 0.095 - 0.911）。线性回归分析表明，ARB组血管重建手术的频率降低（P值0.025；95%CI -1.004 - - 0.068）。
ARB可能是PAD患者一种有前景的保护性治疗选择，通过降低截肢风险和减少血管重建手术需求，可能对疾病进展有益。
